Compounds > levocetirizine

Page last updated: 2024-12-09

levocetirizine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	1549000
CHEMBL ID	1201191
CHEBI ID	94559
SCHEMBL ID	4914
MeSH ID	M0446925

Synonyms (80)

Synonym
BIDD:GT0791
AC-15295
2-[2-[4-[(r)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
gtpl1214
vozet
PDSP1_000269
(2-(4-((r-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid
(-)-cetirizine
acetic acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-
PDSP2_000268
xazal (tn)
levocetirizine (usan/inn)
D07402
130018-77-8
PDSP2_000117
MLS001401375
levocetirizine
MLS000759420
smr000466315
PDSP1_000117
HMS2051N10
(r)-cetirizine
cetirizine, (r)-
cetirizine, (-)-
CHEMBL1201191
xazal
cetirizine (r)-form
2-[2-[4-[(r)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid
A806002
levocetirizine [usan:inn:ban]
xarlin
6u5ea9rt2o ,
unii-6u5ea9rt2o
bdbm85030
cetirizine (-) isomer
HMS2231M24
CCG-101021
levocetirizine [who-dd]
levocetirizine [vandf]
acetic acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)
levocetirizine [mart.]
levocetirizine [usan]
(2-{4-[(r)-(4-chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetic acid
levocetirizine [inn]
cetirizine (r)-form [mi]
S5864
(-)-cetirizine dihydrochloride
AB00639972-08
SCHEMBL4914
ZKLPARSLTMPFCP-OAQYLSRUSA-N
levocetrizine
(2-(4-((r)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid
(r)-2-(2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid
(2-{4-[(r)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
DTXSID60156294 ,
2-(2-{4-[(r)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
DB06282
2-[2-[4-[(r)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid
CHEBI:94559
NCGC00263567-04
r-levocetirizine
HY-B0814
CS-0012812
Q421091
H230000000
singulair and xyzal combination
hcp1102
hcp 1102
(r)-cetirizine (dihydrochloride)
levocetirizine (dihydrochloride)
AKOS016844241
acetic acid, 2-[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-
EN300-20600167
levocetirizine (mart.)
2-(2-(4-((r)-(4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid
levocetirizinum
r06ae09
dtxcid1078785
levocetirizina
(2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid

Research Excerpts

Overview

Levocetirizine is an orally administrated, second-generation antihistaminic active pharmaceutical ingredient that has been used to treat symptoms of allergy and long-term hives for over 25 years. The drug was approved in January 2008 for the relief of symptoms of seasonal allergic rhinitis (SAR), perennial allergic rhinoitis (PAR), and chronic idiopathic urticaria (CIU)

Excerpt	Reference	Relevance
"Levocetirizine is an orally administrated, second-generation antihistaminic active pharmaceutical ingredient that has been used to treat symptoms of allergy and long-term hives for over 25 years. "	( The Elusive Structure of Levocetirizine Dihydrochloride Determined by Electron Diffraction. Alhaddad, Z; Bücker, R; Göb, CR; Karothu, DP; Naumov, P; Schürmann, CJ, 2023)	2.66
"Levocetirizine is a second-generation nonsedative antihistaminic agent that has been demonstrated to be safe and effective for treating allergic disease. "	( A case of levocetirizine-induced liver injury. Cho, JY; Jung, MC; Kim, JK; Kim, SE; Lee, B; Park, JW; Seo, J; Song, JW, 2016)	2.28
"Levocetirizine (LCZ) is a second-generation antihistamine that was approved in January 2008 for the relief of symptoms of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), and chronic idiopathic urticaria (CIU) in adults and children aged > or = 6 years."	( Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children. Borja-Hart, N; Ghin, HL; Perez, A; Robles, GI; Singh-Franco, D, 2009)	3.24
"Levocetirizine 5 mg/day is an effective and well-tolerated treatment of PAR. "	( Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Potter, PC, 2003)	3.2
"Levocetirizine is a new single-isomer antihistamine with a proven efficacy on chronic urticaria as documented in two recent clinical studies, which have included effectiveness and quality of life assessments."	( Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. Kapp, A; Wedi, B, )	1.09
"Levocetirizine is a potent and highly selective H1-antihistamine with a proven efficacy in adults."	( Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Alt, R; Billard, E; de Blic, J; Pujazon, MC; Wahn, U, 2005)	2.49
"Levocetirizine is an antihistamine with high affinity and selectivity for H1-receptors, which exhibits an excellent benefit/risk ratio in the treatment of allergic rhinitis and urticaria. "	( Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. Cranswick, N; Fuchs, M; Hulhoven, R; Turzíkova, J, 2005)	3.21
"Levocetirizine is an antihistamine from the latest generation approved for CIU."	( Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Kapp, A; Pichler, WJ, 2006)	2.5
"Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU). "	( Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Hair, PI; Scott, LJ, 2006)	3.22
"Levocetirizine is a welcome new treatment option in the United States for symptomatic treatment of AR and CIU."	( Levocetirizine: The latest treatment option for allergic rhinitis and chronic idiopathic urticaria. Dubuske, LM, )	2.3
"Levocetirizine is an effective and safe treatment for use in adults and children with allergic disease."	( A review of the role of levocetirizine as an effective therapy for allergic disease. Walsh, GM, 2008)	2.1

Effects

Levocetirizine has been shown in observational studies in the west as an effective and satisfactory therapy for patients with allergic respiratory and skin disease. It is rapidly and extensively absorbed, minimally metabolized, and has a lower volume of distribution (V(d) than some other second-generation antihistamines.

Excerpt	Reference	Relevance
"Levocetirizine has a favorable pharmacokinetic profile; it is rapidly and extensively absorbed, minimally metabolized, and has a lower volume of distribution (V(d)) than some other second-generation antihistamines."	( Levocetirizine: a new selective H1 receptor antagonist for use in allergic disorders. Day, JH; Ellis, AK; Rafeiro, E, 2004)	2.49
"Levocetirizine has modest sedative effects with a risk ratio of 1.67 when compared with placebo. "	( Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Chitsuthipakorn, W; Khattiyawittayakun, L; Seresirikachorn, K; Snidvongs, K, 2017)	2.22
"Levocetirizine has several pharmacokinetic properties that are desirable for an antihistamine providing a combination of both potency and safety. "	( Pharmacokinetic evaluation of levocetirizine. Ferrer, M, 2011)	2.1
"Levocetirizine has been shown in observational studies in the west as an effective and satisfactory therapy for patients with allergic respiratory and skin disease. "	( An open-label, multicentre study of levocetirizine for the treatment of allergic rhinitis and urticaria in Taiwanese patients. Fang, SY; Huangs, CY; Lee, JY; Lin, DY; Perng, DW, 2010)	2.08
"Levocetirizine has a favorable pharmacokinetic profile; it is rapidly and extensively absorbed, minimally metabolized, and has a lower volume of distribution (V(d)) than some other second-generation antihistamines."	( Levocetirizine: a new selective H1 receptor antagonist for use in allergic disorders. Day, JH; Ellis, AK; Rafeiro, E, 2004)	2.49
"Levocetirizine has pharmacodynamically and pharmacokinetically favourable characteristics, including high bioavailability, rapid onset of action, limited distribution and a low degree of metabolism."	( Levocetirizine: an update. Walsh, GM, 2006)	2.5
"Levocetirizine has high bioavailability, high affinity for and occupancy of the H1 receptor, rapid onset of action, limited distribution and minimal hepatic metabolism. "	( A review of the role of levocetirizine as an effective therapy for allergic disease. Walsh, GM, 2008)	2.1

Treatment

Levocetirizine treatment also correlated with a significant increase in the percentage of CD4+CD25+ T cells. Treatment inhibited the HRV-induced increase in ICAM-1 mRNA and protein levels, as well as the HRv-induced expression of IL-6 and IL-8 mRNA and proteins. LevocetIRizine showed no side effects on salivary glands function.

Excerpt	Reference	Relevance
"Levocetirizine treatment also correlated with a significant increase in the percentage of CD4+CD25+ T cells (P<0.001)."	( Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis. Arifhodzic, N; Haines, D; Mahmoud, F; Novotney, L, 2008)	2.51
"Levocetirizine treatment inhibited the HRV-induced increase in ICAM-1 mRNA and protein levels, as well as the HRV-induced expression of IL-6 and IL-8 mRNA and protein levels."	( Levocetirizine inhibits rhinovirus-induced ICAM-1 and cytokine expression and viral replication in airway epithelial cells. Jang, YJ; Kim, JS; Kwon, HJ; Lee, BJ; Wang, JH; Yeo, NK, 2009)	2.52
"Levocetirizine treatment showed no side effects on salivary glands function."	( Evaluation by (99m)Tc-pertechnetate scintigraphy of the effect of levocetirizine on salivary glands function, in allergic rhinitis patients. Kursad Ayan, A; Sahin, A; Seven, B; Sutbeyaz, Y; Ucuncu, H; Varoglu, E; Yoruk, O, )	1.09
"Levocetirizine treatment induced significant symptom relief (P=0.0009) and improved nasal airflow (P=0.038). "	( Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Ciprandi, G; Cirillo, I; Tosca, MA; Vizzaccaro, A, 2004)	3.21
"Levocetirizine treatment induced: significant symptom relief (p<0.001), improved nasal airflow (p<0.001), reduction of reversibility percentage (p<0.05), and increase of total airflow after decongestion test (p<0.03). "	( Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. Ciprandi, G; Cirillo, IG; Tosca, MA; Vizzaccaro, A, 2005)	3.21
"Treatment with levocetirizine caused significant decreases in AUCOGTT, AUCITT, HOMA-IR, hepatic GSH and MDA levels and serum CRP level and LDH activity and significant increases in hepatic SOD activity and HOMA-β when compared with the HFD group."	( Levocetirizine ameliorates high fructose diet-induced insulin resistance, vascular dysfunction and hepatic steatosis in rats. Abdel Rahim, M; Gameil, NM; Shawky, NM; Shehatou, GS; Suddek, GM, 2014)	2.18
"Treatment with levocetirizine reduces the cost of persistent allergic rhinitis and its comorbidities to the society by 152.93/patient/month while improving symptoms and health-related quality of life."	( Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Bachert, C; Bousquet, J; Demarteau, N; Mullol, J; van den Akker-van Marle, ME; Van Ganse, E, 2005)	0.91

Toxicity

Olopatadine is a safe and more effective alternative to levocetirizine in the treatment of CU.

Excerpt	Reference	Relevance
" Incidence of treatment-emergent adverse events was similar in both groups (33."	( Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Alt, R; Billard, E; de Blic, J; Pujazon, MC; Wahn, U, 2005)	1.77
"01), and the frequency of adverse events did not differ significantly from those seen in the placebo group."	( Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Potter, PC, 2005)	0.64
" Safety was assessed by: reporting of adverse events, numbers of children discontinuing the study because of adverse events, height and body mass measurements, assessment of developmental milestones, and hematology and biochemistry tests."	( Safety of levocetirizine treatment in young atopic children: An 18-month study. Simons, FE, 2007)	0.74
" Safety was assessed according to adverse events, laboratory tests and electrocardiograms."	( Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Antépara, I; Bogacka, E; Jáuregui, I; Medina, I; Oanta, A; Uhl, P; Valiente, R; Wesel, F; Zuberbier, T, 2010)	0.6
" Comparison with levocetirizine indicated both treatments to be equally efficacious as well as equally safe and well tolerated as compared with placebo."	( Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Antépara, I; Bogacka, E; Jáuregui, I; Medina, I; Oanta, A; Uhl, P; Valiente, R; Wesel, F; Zuberbier, T, 2010)	0.94
"Bilastine 20 mg is a novel effective and safe treatment option for the management of CU."	( Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Antépara, I; Bogacka, E; Jáuregui, I; Medina, I; Oanta, A; Uhl, P; Valiente, R; Wesel, F; Zuberbier, T, 2010)	0.6
" Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population."	( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Moeller, ML; Nahata, MC; Phan, H, 2009)	0.35
" Overall incidence of treatment-emergent adverse events was 14."	( Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Gawchik, S; Georges, G; Haeusler, JM; Segall, N, 2010)	0.67
" Incidence of adverse effects was less in the rupatadine group compared with the levocetirizine group."	( Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. Allala, U; Jaida, J; Maiti, R; Palani, A; Rahman, J, 2010)	0.94
" Safety evaluations included treatment-emergent adverse events (TEAEs), vital signs, electrocardiographic (ECG) assessments, and laboratory tests."	( Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Haeusler, JM; Hampel, F; Ratner, P, )	0.43
" The first-generation H(1)-antihistamines are associated with marked adverse effects such as sedation, sleepiness/drowsiness as well as difficulties in learning and cognitive processing; thus, they are recommended for limited or discontinued use in children with AR or CIU."	( Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. Kurzawa, R; Pampura, AN; Papadopoulos, NG; Spičák, V, 2011)	0.6
" The overall incidence of adverse drug reactions was also found to be less in rupatadine group."	( Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. Ahmed, I; Goud, P; Jaida, J; Maiti, R; Palani, A; Raghavendra, BN, 2011)	0.72
" Routine hematological and biochemical tests and treatment-emergent adverse events were monitored for safety."	( Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety. Bagchi, C; Chaudhuri, A; Das, NK; Hazra, A; Islam, CN; Sil, A; Tripathi, SK, 2013)	0.72
" Adverse event profiles were comparable with sedation being the commonest complaint."	( Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety. Bagchi, C; Chaudhuri, A; Das, NK; Hazra, A; Islam, CN; Sil, A; Tripathi, SK, 2013)	0.72
"Olopatadine is a safe and more effective alternative to levocetirizine in the treatment of CU."	( Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety. Bagchi, C; Chaudhuri, A; Das, NK; Hazra, A; Islam, CN; Sil, A; Tripathi, SK, 2013)	0.96
" Routine hematological and biochemical tests and treatment-emergent adverse events were monitored for safety."	( Effectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial. Das, NK; Ghosh, C; Pal, S; Sarkar, TK; Sil, A, )	0.43
"The fixed-dose combination of montelukast and levocetirizine was effective and safe in treating perennial allergic rhinitis in patients with asthma compared with montelukast alone."	( A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis. Chang, YS; Cho, YJ; Cho, YS; Choi, BW; Chung, JH; Jee, YK; Jo, EJ; Jung, J; Kim, HK; Kim, MK; Kim, SH; Lee, BJ; Lee, JM; Lee, SK; Lee, SY; Park, CS; Park, HS; Park, HW; Park, JW; Yoo, KH; Yoon, HJ, 2018)	0.94
" Safety was assessed by recording drug-related adverse events, biochemical investigations, and electrocardiogram, along with tolerability and compliance."	( Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial. Biswas, D; Chowdhury, SN; Das, A; Ghosh, S; Podder, I; Sengupta, S, 2020)	0.8
"The aim of the study was to evaluate the treatment effects and adverse events of Monterizine® (a combination of montelukast and levocetirizine); a total of 2,254 patients with perennial allergic rhinitis and asthma were prospectively enrolled from 60 hospitals nationwide in Korea."	( Multicenter Prospective Observational Study to Evaluate the Therapeutic Effect and Safety of a Combination of Montelukast and Levocetirizine for Allergic Rhinitis when Administered to Patients with Allergic Rhinitis and Asthma. Cho, YJ; Choi, BW; Jung, JW; Kim, MH; Kwon, JW; Nam, YH; Park, CS; Park, HJ; Park, JS; Shin, YS; Sohn, KH, 2022)	1.13
" There were no serious adverse drug reactions, but there were some minor reactions including nasopharyngitis (2."	( Multicenter Prospective Observational Study to Evaluate the Therapeutic Effect and Safety of a Combination of Montelukast and Levocetirizine for Allergic Rhinitis when Administered to Patients with Allergic Rhinitis and Asthma. Cho, YJ; Choi, BW; Jung, JW; Kim, MH; Kwon, JW; Nam, YH; Park, CS; Park, HJ; Park, JS; Shin, YS; Sohn, KH, 2022)	0.93
"TNSS score and QoL were significantly improved by 3-6 months' treatment with Monterizine without significant adverse reactions."	( Multicenter Prospective Observational Study to Evaluate the Therapeutic Effect and Safety of a Combination of Montelukast and Levocetirizine for Allergic Rhinitis when Administered to Patients with Allergic Rhinitis and Asthma. Cho, YJ; Choi, BW; Jung, JW; Kim, MH; Kwon, JW; Nam, YH; Park, CS; Park, HJ; Park, JS; Shin, YS; Sohn, KH, 2022)	0.93

Pharmacokinetics

The aim of this study is to assess the bioequivalence of a new generic formulation and the branded formulation of levocetirizine dihydrochloride in healthy Chinese volunteers. The food-intake effect on the pharmacokinetic properties is also evaluated.

Excerpt	Reference	Relevance
"This study was performed to investigate levocetirizine pharmacokinetic disposition and pharmacodynamics in relation to skin reactivity to histamine in children aged 6 to 11 years."	( Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. Simons, FE; Simons, KJ, 2005)	2.04
" It is concluded that estimating in vivo receptor occupancy, which takes into account both the affinity of the drug for the receptor and its free plasma concentration, is a far better predictor for human pharmacodynamics and hence antihistamine potency, than considering in vitro affinity and plasmatic half-life only."	( Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Baltes, E; Benedetti, MS; Chatelain, P; Gillard, M, 2005)	0.33
" The recommended dose of levocetirizine is 5 mg once daily, while its pharmacokinetic half-life is about 7 h in humans."	( Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Chen, C, 2008)	0.86
"Levocetirizine has several pharmacokinetic properties that are desirable for an antihistamine providing a combination of both potency and safety."	( Pharmacokinetic evaluation of levocetirizine. Ferrer, M, 2011)	2.1
" The validated method was applied in a pharmacokinetic study to determine the concentration of levocetirizine in plasma samples."	( Determination of levocetirizine in human plasma by LC-MS-MS: validation and application in a pharmacokinetic study. Jithavech, P; Rojsitthisak, P; Sanphanya, K; Vicheantawatchai, P; Wichitnithad, W, )	0.69
"The aim of this study is to assess the bioequivalence of a new generic formulation and the branded formulation of levocetirizine dihydrochloride in healthy Chinese volunteers under fasting and fed conditions, and food-intake effect on the pharmacokinetic properties is also evaluated."	( The Effect Of Food On The Pharmacokinetic Properties And Bioequivalence Of Two Formulations Of Levocetirizine Dihydrochloride In Healthy Chinese Volunteers. Chen, XF; Cheng, Y; Fang, LP; Guo, JH; Huang, BL; Lin, BJ; Liu, MB; Qiu, HQ; Que, WC, 2019)	0.94
"The two formulations demonstrated essentially identical pharmacokinetic profiles and were all well within the FDA/CFDA bioequivalence standards."	( The Effect Of Food On The Pharmacokinetic Properties And Bioequivalence Of Two Formulations Of Levocetirizine Dihydrochloride In Healthy Chinese Volunteers. Chen, XF; Cheng, Y; Fang, LP; Guo, JH; Huang, BL; Lin, BJ; Liu, MB; Qiu, HQ; Que, WC, 2019)	0.73
" The objective of this study was to compare the pharmacokinetic profiles of a montelukast/levocetirizine fixed-dose combination chewable tablet with individual administration of montelukast and levocetirizine in healthy subjects."	( Comparative pharmacokinetics of a montelukast/levocetirizine fixed-dose combination chewable tablet versus individual administration of montelukast and levocetirizine after a single oral administration in healthy Korean male subjects . Jung, J; Kim, MG; Kim, YI; Moon, SJ; Yu, KS, 2020)	1.04
"A total of 22 subjects were included in pharmacokinetic analysis."	( Comparative pharmacokinetics of a montelukast/levocetirizine fixed-dose combination chewable tablet versus individual administration of montelukast and levocetirizine after a single oral administration in healthy Korean male subjects . Jung, J; Kim, MG; Kim, YI; Moon, SJ; Yu, KS, 2020)	0.82
"The pharmacokinetic parameters of montelukast and levocetirizine when administered as separate tablets or as a fixed-dose combination were compared, and the parameters met the pharmacokinetic equivalence criteria."	( Comparative pharmacokinetics of a montelukast/levocetirizine fixed-dose combination chewable tablet versus individual administration of montelukast and levocetirizine after a single oral administration in healthy Korean male subjects . Jung, J; Kim, MG; Kim, YI; Moon, SJ; Yu, KS, 2020)	1.07

Compound-Compound Interactions

Excerpt	Reference	Relevance
"Montelukast alone or in combination with antihistamines gave a gradual increase in nasal symptom improvement within 6 weeks of treatment in patients with persistent AR."	( Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. Barylski, M; Ciebiada, M; Gorska-Ciebiada, M; Gorski, P; Kmiecik, T, )	0.37
"Levocetirizine dihydrochloride is known to interact with some anti-inflammatory drugs."	( In vitro drug interaction of levocetirizine and diclofenac: Theoretical and spectroscopic studies. Abdel Gaber, SA; Abo Dena, AS, 2017)	2.19

Bioavailability

The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose. The estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.

Excerpt	Reference	Relevance
" The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine."	( Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Benedetti, MS; Diquet, B; Molimard, M, 2004)	0.78
" Validation results on linearity, specificity, accuracy, precision and stability, as well as its application to the analysis of plasma samples taken up to 48h after oral administration of 5mg of levocetirizine dichloridrate in healthy volunteers demonstrate its applicability to bioavailability studies."	( Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. Abib, E; Amarante, AR; Barros, FA; Berton, D; Boldin, R; Calafatti, SA; Campos, DR; Meurer, EC; Morita, MR; Pedrazolli, J; Pereira, R, 2008)	0.87
" No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules."	( Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Devillier, P; Faisy, C; Roche, N, 2008)	0.79
" Cetirizine exhibits high intestinal absorption in humans and its oral bioavailability is estimated to be greater than 70%."	( Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Chen, C, 2008)	0.56
" The compound shows a rapid onset of action, high bioavailability and affinity for the H1 receptor."	( Levocetirizine in the treatment of allergic diseases. Baiardini, I; Canonica, GW; Compalati, E; Scordamaglia, A; Scordamaglia, F, 2009)	1.8
" Moreover, the use of these effervescent tablets in an orodispersible dosage form can improve oral drug bioavailability and act as an attractive pediatric dosage form."	( Novel levocetirizine HCl tablets with enhanced palatability: synergistic effect of combining taste modifiers and effervescence technique. Labib, GS, 2015)	0.9
" Moreover, levocetirizine attenuated the elevated renal levels of TNF-α and TGF-β1, ameliorated renal oxidative stress and restored NO bioavailability in diabetic kidney."	( Comparison of the effects of levocetirizine and losartan on diabetic nephropathy and vascular dysfunction in streptozotocin-induced diabetic rats. Anbar, HS; Gameil, NM; Shehatou, GS; Suddek, GM, 2016)	1.12
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Meanwhile, food intake can delay the absorption rate and reduced the bioavailability of levocetirizine in healthy Chinese volunteers."	( The Effect Of Food On The Pharmacokinetic Properties And Bioequivalence Of Two Formulations Of Levocetirizine Dihydrochloride In Healthy Chinese Volunteers. Chen, XF; Cheng, Y; Fang, LP; Guo, JH; Huang, BL; Lin, BJ; Liu, MB; Qiu, HQ; Que, WC, 2019)	0.95
" Part 1 compared the bioavailability of levocetirizine oral disintegrating tablet (ODT) and levocetirizine immediate-release tablet (IRT) taken with water in the fasted state in 24 subjects; all subjects completed this part of the trial."	( Levocetirizine Oral Disintegrating Tablet: A Randomized Open-Label Crossover Bioequivalence Study in Healthy Japanese Volunteers. Eto, T; Haranaka, M; Hoyano, K; Ino, H; Irie, S; Nakano, A; Ogura, H; Shiramoto, M; Terao, T; Wakamatsu, A, 2020)	2.27
" Levocetirizine's solubility and permeability properties, as well as its dissolution from commercial products, its therapeutic uses, therapeutic index, pharmacokinetics and pharmacodynamic traits, were reviewed in accordance with the BCS, along with any reports in the literature about failure to meet bioequivalence (BE) requirements, bioavailability issues, drug-excipient interactions as well as other relevant information."	( Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Levocetirizine Dihydrochloride. Abdallah, DB; Abrahamsson, B; Ahmed, DT; Charoo, NA; Cristofoletti, R; Dressman, J; Kambayashi, A; Langguth, P; Mehta, M; Parr, A; Polli, JE; Shah, VP, 2023)	2.06
" However, the bioavailability of levocetirizine hydrochloride granules remains to be determined."	( Bioequivalence of Levocetirizine Hydrochloride Granules (Kangzhitai) in Healthy Subjects. Tan, H; Xiang, H; Yang, G, 2023)	1.53
" The relative bioavailability (F, assessed by AUC0-48) of Kangzhitai® vs."	( Bioequivalence of Levocetirizine Hydrochloride Granules (Kangzhitai) in Healthy Subjects. Tan, H; Xiang, H; Yang, G, 2023)	1.24

Dosage Studied

Increasing the dosage of levocetirizine and desloratadine up to 4-fold improves chronic urticaria symptoms without compromising safety in approximately three quarters of patients. These results suggest that double-dosed le Vocetirzine treatment suppresses histamine-induced skin symptoms more rapidly, profoundly and sustainably.

Excerpt	Relevance	Reference
" Compliance with cetirizine dosing was documented."	( Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective. Simons, FE, 2005)	0.61
" Once-daily dosing may be optimal in children aged 6 to 11 years, as it is in adults."	( Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. Simons, FE; Simons, KJ, 2005)	1.77
" DAD detection was utilized for the characterization of composition of each separated zone via match of corresponding tested (analyte in dosage form) and reference (standard analyte in water) UV-VIS spectrum (scanned in interval 200-800 nm) being expressed mathematically through Pearson's correlation coefficient (PCC)."	( Enantiomeric purity control of levocetirizine in pharmaceuticals using anionic cyclodextrin mediated capillary electrophoresis separation and fiber-based diode array detection. Havránek, E; Maráková, K; Mikus, P; Valásková, I, 2009)	0.64
" Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast."	( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Moeller, ML; Nahata, MC; Phan, H, 2009)	0.35
"Increasing the dosage of levocetirizine and desloratadine up to 4-fold improves chronic urticaria symptoms without compromising safety in approximately three quarters of patients with difficult-to-treat chronic urticaria."	( The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. Church, DS; Church, MK; Dimitrov, V; Kraeva, S; Kralimarkova, T; Lazarova, C; Popov, TA; Popova, D; Staevska, M, 2010)	0.98
" Thus, the proposed method is suitable for the simultaneous analysis of active ingredients in tablet dosage forms and human serum."	( Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC. Arayne, MS; Mirza, AZ; Siddiqui, FA; Sultana, N, )	0.36
" These results suggest that double-dosed levocetirizine treatment suppresses histamine-induced skin symptoms more rapidly, profoundly and sustainably than conventionally dosed levocetirizine treatment."	( A double dose of levocetirizine leads to better control of histamine-induced flare, wheal and itch in healthy donors. Kabashima, K; Miyachi, Y; Nakahigashi, K; Nakamizo, S; Tanizaki, H, 2013)	1
" Moreover, the use of these effervescent tablets in an orodispersible dosage form can improve oral drug bioavailability and act as an attractive pediatric dosage form."	( Novel levocetirizine HCl tablets with enhanced palatability: synergistic effect of combining taste modifiers and effervescence technique. Labib, GS, 2015)	0.9
" The developed methods have been successfully applied to the simultaneous determination of both drugs in commercial tablet dosage form."	( Validated derivative and ratio derivative spectrophotometric methods for the simultaneous determination of levocetirizine dihydrochloride and ambroxol hydrochloride in pharmaceutical dosage form. Ali, OI; Elgohary, RM; Ismail, NS, 2016)	0.65
" The EAACI/GA[2]LEN/EDF/WAO guidelines advocate an increased antihistamine dosage up to four times the standard, before adding leukotriene receptor antagonists."	( Effectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial. Das, NK; Ghosh, C; Pal, S; Sarkar, TK; Sil, A, )	0.43
" One oral dose of vehicle, LEVO (10 mg/kg/species) or moxifloxacin (MOXI; 30 mg/kg/dog; 80 mg/kg/NHP) was administered to instrumented animals (N = 8/species) using a cross-over dosing design; MOXI was the in-study positive control."	( Evaluation of levocetirizine in beagle dog and cynomolgus monkey telemetry assays: Defining the no QTc effect profile by timepoint and concentration-QTc analysis. Baublits, J; Chandra, FA; Chui, RW; Engwall, MJ; Jones, ZW; Vargas, HM; Wahlstrom, J, 2023)	1.27
"One of the most important issues for bitter-tasting drugs such as levocetirizine dihydrochloride (LCD) is the production of palatable dosage forms."	( Palatable Levocetirizine Dihydrochloride Solid Dispersed Fast-Dissolving Films: Formulation and Ahmed, MA; Al-Kubati, SS; Emad, NA, 2022)	1.36
" In this monograph, the practicality of using Biopharmaceutics Classification System (BCS) based methodologies as a substitute for pharmacokinetic studies in human volunteers to appraise the bioequivalence of immediate-release (IR) oral, solid dosage forms containing levocetirizine dihydrochloride was investigated, using data from the literature and in-house testing."	( Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Levocetirizine Dihydrochloride. Abdallah, DB; Abrahamsson, B; Ahmed, DT; Charoo, NA; Cristofoletti, R; Dressman, J; Kambayashi, A; Langguth, P; Mehta, M; Parr, A; Polli, JE; Shah, VP, 2023)	1.33
"A novel potentiometric sensor which consists of a silver wire coated with zinc oxide (ZnO) nanorod modified with a polymeric membrane (combining β-cyclodextrin and tetraphenyl borate, and plasticized with di-butyl phthalate) was constructed for the determination of LVZ·2HCl in its pure form and its combination dosage form."	( Construction of a Zinc Oxide Nanorod-Modified Coated Wire Electrode for Potentiometric Determination of Levocetirizine Dihydrochloride in Its Pure and Combined Form. Alhaj Sakur, A; Nashed, D; Noureldin, I, 2023)	1.12
"The method was validated according to International Council for Harmonisation of Technical Requirments for Registration of Pharmaceuticals for Human Use (ICH) rules and applied to the determination of LVZ in its pure and combined pharmaceutical dosage forms."	( Construction of a Zinc Oxide Nanorod-Modified Coated Wire Electrode for Potentiometric Determination of Levocetirizine Dihydrochloride in Its Pure and Combined Form. Alhaj Sakur, A; Nashed, D; Noureldin, I, 2023)	1.12

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
diarylmethane	Any compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

Pathway	Proteins	Compounds
Levocetirizine H1-Antihistamine Action	8	7

Protein Targets (8)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	89.1251	0.6310	35.7641	100.0000	AID504339
USP1 protein, partial	Homo sapiens (human)	Potency	89.1251	0.0316	37.5844	354.8130	AID743255
cytochrome P450 2D6	Homo sapiens (human)	Potency	26.8370	0.0010	8.3798	61.1304	AID1645840
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	79.4328	0.7079	36.9043	89.1251	AID504333
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	39.8107	0.0355	20.9770	89.1251	AID504332
beta-2 adrenergic receptor	Homo sapiens (human)	Potency	10.0000	0.0058	6.0263	32.6427	AID492947
transcriptional regulator ERG isoform 3	Homo sapiens (human)	Potency	7.9433	0.7943	21.2757	50.1187	AID624246
geminin	Homo sapiens (human)	Potency	28.1838	0.0046	11.3741	33.4983	AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay ID	Title	Year	Journal	Article
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1202698	Plasma protein binding in guinea pig	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID1578091	Unbound brain-to-plasma concentration ratio in guinea pig	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
AID1202697	Ratio of unbound drug in brain to plasma in iv dosed guinea pig	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID1202696	Ratio of drug uptake in brain to plasma in iv dosed guinea pig	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID1578088	Brain to plasma partition coefficient, Kp of the compound in guinea pig	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
AID1578089	Plasma protein binding in guinea pig	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
AID1202699	Plasma protein binding in human	2015	Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6	CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346037	Human H1 receptor (Histamine receptors)	2004	European journal of biochemistry, Jul, Volume: 271, Issue:13	Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (254)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	115 (45.28)	29.6817
2010's	106 (41.73)	24.3611
2020's	33 (12.99)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 127.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	127.31 (24.57)
Research Supply Index	6.01 (2.92)
Research Growth Index	4.52 (4.65)
Search Engine Demand Index	244.67 (26.88)
Search Engine Supply Index	2.07 (0.95)

This Compound (127.31)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	110 (37.16%)	5.53%
Reviews	43 (14.53%)	6.00%
Case Studies	30 (10.14%)	4.05%
Observational	2 (0.68%)	0.25%
Other	111 (37.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (69)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy and Safety of Levocetirizine Alone or in Combination With Tranexamic Acid in the Treatment of Spontaneous Chronic Urticaria. Multicentric Controlled Randomized Study in Cross-over, Double-blind [NCT03789422]	Phase 4	80 participants (Anticipated)	Interventional	2019-12-10	Recruiting
Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study [NCT01250652]	Phase 4	24 participants (Actual)	Interventional	2011-03-31	Completed
A Single Centre, Single Dose, Open-label, Randomized, 2-part, 2-way Crossover Study to Determine the Bioequivalence of Levocetirizine Oral Disintegrating Tablet Given With Water and Without Water Compared to Levocetirizine Immediate Release Tablet in Heal [NCT03555890]	Phase 1	72 participants (Actual)	Interventional	2018-05-18	Completed
The Early Prevention of Asthma in Atopic Children (EPAAC™) Study. A Multi-country, Double Blind, Placebo (PLC) Controlled, Randomized, Parallel Group Trial: Evaluation of the Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b. [NCT00152464]	Phase 3	514 participants (Actual)	Interventional	2002-03-20	Completed
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria. [NCT00628108]	Phase 3	69 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Levocetirizine Dihydrochloride 5 mg Tablets With Xyzal® 5 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fed Condition [NCT01567501]	Phase 1	28 participants (Actual)	Interventional	2012-02-29	Completed
The Effects of Desloratadine and Levocetirizine on Nasal Obstruction in Subjects With Induced Allergic Rhinitis in the VCC Assessed Clinically and With Nasal Rhinomanometry and Nasal Flowmetry [NCT00789152]	Phase 3	81 participants (Actual)	Interventional	2003-12-01	Completed
A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of [NCT00619801]	Phase 3	173 participants (Actual)	Interventional	2008-03-31	Completed
A Phase 1, Randomized, Placebo-controlled, Participant- and Investigator-blind, Single-dose Study of the Pharmacokinetics of LY3471851 Following Subcutaneous Dosing of LY3471851 in Healthy Participants [NCT05565729]	Phase 1	41 participants (Actual)	Interventional	2022-10-05	Completed
Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study [NCT00884325]	Phase 4	40 participants (Actual)	Interventional	2009-02-28	Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Al [NCT00621959]	Phase 4	596 participants (Actual)	Interventional	2008-03-31	Completed
A Randomised Controlled Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria [NCT03991845]	Phase 4	262 participants (Actual)	Interventional	2019-06-21	Enrolling by invitation
A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis [NCT00679250]	Phase 4	25 participants (Actual)	Interventional	2005-11-30	Completed
Is Levocetirizine Less Sedating Than Cetirizine? A Randomized, Double-blind, Placebo Controlled Trial. [NCT00826943]	Phase 4	30 participants (Actual)	Interventional	2009-01-31	Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Al [NCT00653224]	Phase 4	580 participants (Actual)	Interventional	2008-04-30	Completed
Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis [NCT00894231]	Phase 4	30 participants (Anticipated)	Interventional	2009-01-31	Completed
Comparison of Efficacy, Safety and Cost Effectiveness of Montelukast and Levocetirizine Versus Montelukast and Fexofenadine in Patients of Allergic Rhinitis: a Randomized, Double-blind Clinical Trial [NCT02551536]	Phase 4	70 participants (Actual)	Interventional	2014-04-30	Completed
A Randomized, Parallel, Double-blind, Multi-center, Comparative Study to Exploratively Evaluate the Efficacy and Safety of Cosalin® Monotherapy vs. Cosalin® and Xarlin® Combination Therapy in Patients With Allergic Rhinitis [NCT01062139]	Phase 4	100 participants (Actual)	Interventional	2009-10-31	Enrolling by invitation
3-D Visualization of the Anti-Obstructive Effect of Levocetirizine - A Monocentric Clinical Trail With One Patient (Phase-IV-Study) [NCT01000792]	Phase 3	1 participants (Actual)	Interventional	2009-11-30	Completed
The Effect of Levocetirizine (Xyzal®) on the Skin Levels of Inflammatory Mediators Histamine, Serine Proteases, Prostaglandin E2, Leukotriene B4 and Cathepsins in Patients With Symptomatic Dermatographism and Chronic Idiopathic Urticaria [NCT01008592]		11 participants (Actual)	Observational	2009-04-30	Terminated(stopped due to Mediators of interest were not consistently detectable with the analytical methods employed.)
Evaluation of Efficacy, Using the Number of Comfortable Days and the Safety of Levocetirizine Dihydrochloride, Administered Once Daily in the Evening for 30 Days, to Subjects Suffering From Perennial Allergic Rhinitis to House Dust Mites [NCT00521131]	Phase 4	453 participants (Actual)	Interventional	2002-09-30	Completed
Randomized, Monocenter, Double Blind, Placebo-controlled, Single Oral Dose, Three-way Cross Over Study, to Compare Levocetirizine and Desloratadine on Allergen-induced Wheal and Flare Reaction During 24 Hours in 18 Adult Allergic Volunteers. [NCT00521170]	Phase 1	0 participants	Interventional	2004-11-30	Completed
A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Perennial Allergic Rhinitis. [NCT00524836]	Phase 3	71 participants (Actual)	Interventional	2003-09-30	Completed
A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Chronic Idiopathic Urticaria (CIU) [NCT00525382]	Phase 3	134 participants (Actual)	Interventional	2003-08-31	Completed
A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Sufferin [NCT00160589]	Phase 4	729 participants	Interventional	2005-04-30	Completed
A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU) [NCT00264303]	Phase 4	886 participants (Actual)	Interventional	2005-12-31	Completed
COrticosteroids in acUte uRticAria in emerGency dEpartment [NCT03545464]	Phase 3	240 participants (Anticipated)	Interventional	2019-09-21	Recruiting
The Prolongation of the EPAAC™ Trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). A Multi-country, Double Blind, Placebo (PLC) Controlled, Follow-up Trial With 3 Parallel Groups (LCTZ-LCTZ, LCTZ-PLC and PLC-PLC) : Evaluation of the L [NCT00160563]	Phase 3	207 participants (Actual)	Interventional	2004-06-30	Terminated(stopped due to The predecessor study A00309 (NCT00152464) did not show statistical significance in time to onset of asthma between the levocetirizine and placebo groups.)
Double Blind, Double-dummy, Five Parallel Groups, Randomized, Exploratory Clinical Trial to Compare the Efficacy of Single Dose of Levocetirizine 2.5 mg Oral Drops (5 mg/mL), Levocetirizine 5 mg Oral Tablets, Cetirizine 5 mg Oral Drops (10 mg/mL) and Ceti [NCT00291642]	Phase 2	551 participants (Actual)	Interventional	2006-01-01	Completed
Double-blind, Three Parallel Randomized Groups, Therapeutic Confirmatory Clinical Trial to Compare the Efficacy of Oral Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Ragweed Sensitive Subj [NCT00295022]	Phase 4	418 participants (Actual)	Interventional	2006-07-29	Completed
Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial [NCT01640535]	Phase 3	283 participants (Actual)	Interventional	2012-06-30	Completed
Trial to Compare the Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects Exposed to Pollen Challenge in an Environmental Exposure Unit (EEU). [NCT00544388]	Phase 3	570 participants (Actual)	Interventional	2004-04-30	Completed
A Multi-center, Open, Randomized, Three-arm, Parallel-group, Phase IV Study to Compare the Efficacy of Ciclesonide Nasal Spray and Levocetirizine, Alone and in Combination for the Patient With Allergic Rhinitis [NCT01430260]	Phase 4	349 participants (Actual)	Interventional	2011-01-31	Completed
Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Seasonal Allergic Rhinitis (SAR) [NCT00525278]	Phase 3	67 participants (Actual)	Interventional	2003-08-31	Completed
Open Label, Randomized, 6-sequence Crossover Study to Evaluate the Drug-drug Interaction Between Montelukast Sodium and Levocetirizine Dihydrochloride in Health Male Volunteers [NCT01491503]	Phase 1	30 participants (Anticipated)	Interventional	2011-11-30	Completed
Evaluation of the Efficacy and Safety of Levocetirizine During 8 Weeks Preceding and Following the Anticipated Onset of the Grass Pollen Season in Subjects Suffering From Seasonal Allergic Rhinitis Associated With Pollen-induced Asthma [NCT00521040]		459 participants (Actual)	Interventional	2004-02-29	Completed
The Efficacy and Safety of Levocetirizine Dihydrochloride Oral Drops Given 0.125 mg/kg b.i.d. During 90 Days in the Treatment of Recurrent Cough Associated With Other Allergic Symptoms, e.g. Wheezing, in Children Aged 1-2 Years. [NCT00520754]	Phase 2	15 participants (Actual)	Interventional	2001-12-31	Completed
Trial to Compare the Efficacy and Safety of Levocetirizine 5 mg od and Fexofenadine 120 mg od in Reducing Symptoms of Seasonal Allergic Rhinitis in Grass Pollen Sensitized Adults [NCT00542607]	Phase 4	94 participants (Actual)	Interventional	2002-09-30	Completed
Influence of H1-antihistamines on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin [NCT04399525]		12 participants (Actual)	Interventional	2019-10-28	Completed
Double-blind, 3 Parallel Randomized Groups, Therapeutic Confirmatory. Clinical Trial to Compare the Efficacy of Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects in an EEC. [NCT00315523]	Phase 3	403 participants	Interventional	2006-07-31	Completed
A 4 Week Open, Multi-center Study Evaluating the Safety of Levocetirizine 1.25 mg b.i.d. Given as 0.5 mg/mL Oral Solution in 2 to 6 Year-old Children Suffering From Allergic Rhinitis. [NCT00152412]	Phase 2	30 participants	Interventional	2004-06-30	Completed
A Randomized, Double-blind, Double Dummy, Placebo Controlled, Cross-over Exploratory Trial in Healthy Male Adult Subjects: Comparison by Means of Infrared Thermography of the Anti-H1 Potency of Levocetirizine 5 mg and Cetirizine 10 mg Tablet Single Oral D [NCT00150761]	Phase 4	60 participants	Interventional	2004-07-31	Completed
Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria [NCT00421109]	Phase 3	522 participants (Actual)	Interventional	2006-07-31	Completed
Efficacy of Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Rhinitis [NCT00439712]	Phase 4	60 participants (Actual)	Interventional	2007-02-28	Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL® Tablets 5 mg in Healthy Subjects Under Fasting Conditions [NCT01506076]	Phase 1	29 participants (Actual)	Interventional	2007-12-31	Completed
A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal All [NCT00160537]	Phase 4	200 participants	Interventional	2005-05-31	Completed
A Single Blind, Randomized, Single Oral Dose Study to Compare the Oral Disposition of Levocetirizine When Given Alone (5mg) or as the Racemate (Cetirizine 10mg), and to Investigate the Safety and Tolerability and the Pharmacokinetics of Levocetirizine and [NCT02447393]	Phase 1	20 participants (Actual)	Interventional	2008-03-18	Completed
A Multi-centre, Double-blind, Double-dummy, Randomized, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of Xyzal® 5mg od vs Zyrtec® 10mg od in Subjects Aged 15 Years and Above With Dermatitis and Eczema [NCT00375713]	Phase 3	466 participants (Actual)	Interventional	2005-10-31	Completed
Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (OME) Compared to That of Combination of Antibiotic, Antihistaminic, and Nasal Decongestant [NCT03590912]	Phase 4	160 participants (Actual)	Interventional	2018-09-05	Completed
A Double-blind, Double-dummy, Parallel-group, Placebo-controlled, Randomized Study to Assess the Duration of the Suppressive Effects of Desloratadine on the Cutaneous Allergen-induced Wheal and Flare (1) Response After Discontinuation [NCT00359138]	Phase 4	36 participants (Actual)	Interventional	2006-02-28	Completed
A Pilot, Open, Monocenter, Randomized Two Parallel Groups, Clinical Efficacy Trial: Comparison Continuous Versus on Demand Regimen of Treatment With Levocetirizine 5 mg Oral Tablets, Once a Day, in Adults Suffering From Persistent Allergic Rhinitis (PER) [NCT00160680]	Phase 4	62 participants (Actual)	Interventional	2005-03-01	Completed
Camillian Saint Mary's Hospital Luodong [NCT05348148]		450 participants (Anticipated)	Interventional	2020-06-16	Recruiting
Study to Investigate the Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving at 2 Bar and 4 Bar in Professional Navy Divers [NCT01496911]	Phase 4	24 participants (Actual)	Interventional	2012-04-30	Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL® Tablets 5 mg in Healthy Subjects Under Fed Conditions [NCT01506063]	Phase 1	31 participants (Actual)	Interventional	2008-01-31	Completed
Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial [NCT01509209]	Phase 3	137 participants (Actual)	Interventional	2011-05-31	Completed
Pharmacokinetic Study of Levocetirizine Oral Solution-An Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, the Safety and Tolerability of Levocetirizine Oral Solution (5 mg) and Cetirizine Dry Syrup (10 mg), Following a Single Dos [NCT01622283]	Phase 1	20 participants (Actual)	Interventional	2012-05-02	Completed
Open-label, Randomized, Single Dose Crossover Study to Evaluate the Pharmacokinetics and Safety of Singulair (10 mg) and Xyzal (5 mg) in Free Combination and Fixed-dose Combination as HCP1102 in Healthy Male Volunteers [NCT01651481]	Phase 1	28 participants (Actual)	Interventional	2012-07-31	Completed
Phase II Study of Levocetirizine in Combination With Capecitabine + Bevacizumab to Overcome Resistance to Anti-angiogenic Therapy in Patients With Refractory Colorectal Cancer [NCT01722162]	Phase 2	47 participants (Actual)	Interventional	2013-04-30	Completed
Drug Use Investigation for XYZAL [NCT01445262]		10,728 participants (Actual)	Observational	2011-02-28	Completed
A Multi-Center, Open-labelled Study to Evaluate the Safety of Levocetirizine Hydrochloride Oral Solution in Children Aged 6 Months to 2 Years With Allergic Rhinitis or Pruritus Associated With the Skin Diseases. [NCT01563081]	Phase 3	60 participants (Actual)	Interventional	2012-04-30	Completed
Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response [NCT01586091]	Phase 4	18 participants (Actual)	Interventional	2011-02-28	Completed
A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma [NCT04699604]	Phase 3	300 participants (Anticipated)	Interventional	2021-04-28	Recruiting
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Levocetirizine Dihydrochloride 5 mg Tablets With Xyzal® 5 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fasting Condi [NCT01557439]	Phase 1	28 participants (Actual)	Interventional	2012-02-29	Completed
Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease [NCT05638880]	Phase 2	60 participants (Anticipated)	Interventional	2022-12-20	Recruiting
Placebo Controlled Pilot Study on the Efficacy of Levocetirizine 5 mg in Reducing Symptoms, Airway Resistance, and Sleep Impairment in Patients With Persistent Allergic Rhinitis [NCT00355771]	Phase 4	100 participants (Actual)	Interventional	2006-06-30	Completed
Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Resistant to the Licensed Dosage [NCT02372604]	Phase 3	15 participants (Actual)	Interventional	2015-07-31	Completed
Characterization of the Role of Histamine in Children With Asthma [NCT01392859]	Phase 2/Phase 3	211 participants (Actual)	Interventional	2011-06-30	Completed
In Vivo Anti-inflammatory Effect of H1 Antihistamines in Allergic Rhinitis [NCT02507635]	Phase 4	115 participants (Actual)	Interventional	2009-02-28	Completed
A Randomized, Open Label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of HCP1102 in Comparison to HGP0813 and HGP1408 Administered in Healthy Male Volunteers [NCT03371849]	Phase 1	24 participants (Actual)	Interventional	2017-07-19	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00152464 (10) [back to overview]	Percentage of Days With Symptoms of Nocturnal Cough
NCT00152464 (10) [back to overview]	Percentage of Subjects Using Medication for Atopic Dermatitis
NCT00152464 (10) [back to overview]	Number of Episodes of Urticaria Per Subject
NCT00152464 (10) [back to overview]	Percentage of Days With Symptoms of Either Wheezing or Nocturnal Cough
NCT00152464 (10) [back to overview]	Percentage of Days With Symptoms of Wheezing
NCT00152464 (10) [back to overview]	Percentage of Subjects With Urticaria
NCT00152464 (10) [back to overview]	Time to Onset of Asthma During the Treatment Period
NCT00152464 (10) [back to overview]	Percentage of Days of Use of Asthma Medication
NCT00152464 (10) [back to overview]	Percentage of Days of Use of Medication for Atopic Dermatitis
NCT00152464 (10) [back to overview]	Percentage of Subjects Using Asthma Medication
NCT00160680 (14) [back to overview]	Mean Weekly Individual Symptoms Scores During the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Individual Symptoms Scores During Month 6 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Individual Symptoms Scores During Month 5 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Individual Symptoms Scores During Month 4 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Individual Symptoms Scores During Month 3 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Individual Symptoms Scores During Month 2 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Individual Symptoms Scores During Month 1 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Weekly Total 4 Symptom Score (T4SS) During the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Total 4 Symptom Score (T4SS) for Month 6 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Total 4 Symptom Score (T4SS) for Month 5 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Total 4 Symptom Score (T4SS) for Month 3 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Total 4 Symptom Score (T4SS) for Month 2 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Total 4 Symptom Score (T4SS) for Month 1 of the Treatment Period
NCT00160680 (14) [back to overview]	Mean Monthly Total 4 Symptom Score (T4SS) for Month 4 of the Treatment Period
NCT00264303 (6) [back to overview]	Mean Score for Pruritus Duration Over the Four Weeks of Treatment
NCT00264303 (6) [back to overview]	Mean Pruritus Severity Score Over the Four Weeks of Treatment
NCT00264303 (6) [back to overview]	Mean Chronic Idiopathic Urticaria (CIU) Composite Score Over the First Week of Treatment
NCT00264303 (6) [back to overview]	Mean Pruritus Severity Score Over the First Week of Treatment
NCT00264303 (6) [back to overview]	Mean Chronic Idiopathic Urticaria (CIU) Composite Score Over the Four Weeks of Treatment
NCT00264303 (6) [back to overview]	Mean Score for Pruritus Duration Over the First Week of Treatment
NCT00291642 (9) [back to overview]	Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I
NCT00291642 (9) [back to overview]	Change From Baseline in the MSC Score Over the Total Treatment Period (Period I + Period II)
NCT00291642 (9) [back to overview]	Change From Baseline in the Total Symptom Complex (TSC) Score Over Period I
NCT00291642 (9) [back to overview]	Change From Baseline in the MSC Score Over Period II
NCT00291642 (9) [back to overview]	Change From Baseline in the Total Symptom Complex (TSC) Score Over Period II
NCT00291642 (9) [back to overview]	Change From Baseline in the Total Symptom Complex (TSC) Score Over the Total Treatment Period (Period I + Period II)
NCT00291642 (9) [back to overview]	Change From Baseline in the Individual Symptom Scores Over Period I
NCT00291642 (9) [back to overview]	Change From Baseline in the Individual Symptom Scores Over Period II
NCT00291642 (9) [back to overview]	Change From Baseline in the Individual Symptom Scores Over the Total Treatment Period (Period I + Period II)
NCT00295022 (26) [back to overview]	Percentage of Subjects, at the End of Period III Who Are Willing to Take the Same Medication During the Next Pollen Season
NCT00295022 (26) [back to overview]	Onset of Action During Period I
NCT00295022 (26) [back to overview]	Global Satisfaction of the Subjects at the End of Period III
NCT00295022 (26) [back to overview]	Change From Baseline in the TSC Score + Nasal Congestion Score Over the Total Treatment Period (Period I + Period II + Period III)
NCT00295022 (26) [back to overview]	Change From Baseline in the TSC Score + Nasal Congestion Score Over Period III
NCT00295022 (26) [back to overview]	Change From Baseline in the TSC Score + Nasal Congestion Score Over Period II
NCT00295022 (26) [back to overview]	Change From Baseline in the TSC Score + Nasal Congestion Score Over Period I
NCT00295022 (26) [back to overview]	Change From Baseline in the Total Symptom Complex (TSC) Score Over the Total Treatment Period (Period I + Period II + Period III)
NCT00295022 (26) [back to overview]	Change From Baseline in the Total Symptom Complex (TSC) Score Over Period III
NCT00295022 (26) [back to overview]	Change From Baseline in the Total Symptom Complex (TSC) Score Over Period II
NCT00295022 (26) [back to overview]	Change From Baseline in the Individual Symptom Scores Over Period I
NCT00295022 (26) [back to overview]	Change From Baseline in the MSC Score Over the Total Treatment Period (Period I + Period II + Period III)
NCT00295022 (26) [back to overview]	Change From Baseline in the MSC Score Over Period III
NCT00295022 (26) [back to overview]	Change From Baseline in the MSC Score Over Period II
NCT00295022 (26) [back to overview]	Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I
NCT00295022 (26) [back to overview]	Change From Baseline in the Total Symptom Complex (TSC) Score Over Period I
NCT00295022 (26) [back to overview]	Variability of Action From Baseline in the MSC Score Over Period III
NCT00295022 (26) [back to overview]	Variability of Action From Baseline in the MSC Score Over Period II
NCT00295022 (26) [back to overview]	Intensity of Action From Baseline in the MSC Score Over Period III
NCT00295022 (26) [back to overview]	Intensity of Action From Baseline in the MSC Score Over Period II
NCT00295022 (26) [back to overview]	Intensity of Action From Baseline in the MSC Score Over Period I
NCT00295022 (26) [back to overview]	Variability of Action From Baseline in the MSC Score Over Period I
NCT00295022 (26) [back to overview]	Change From Baseline in the Individual Symptom Scores Over the Total Treatment Period (Period I + Period II + Period III)
NCT00295022 (26) [back to overview]	Change From Baseline in the Individual Symptom Scores Over Period III
NCT00295022 (26) [back to overview]	Change From Baseline in the Individual Symptom Scores Over Period II
NCT00295022 (26) [back to overview]	Time to First Feeling of Improvement During Period I
NCT00359138 (1) [back to overview]	Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment
NCT00375713 (4) [back to overview]	Global Improvement at Endpoint During the 14 Day Treatment Period
NCT00375713 (4) [back to overview]	Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score).
NCT00375713 (4) [back to overview]	Change From Baseline in the Mean Pruritus Severity Score at Endpoint During the 14 Day Treatment Period
NCT00375713 (4) [back to overview]	Duration of Pruritus (Stated in Categories) at Endpoint During the 14 Day Treatment Period
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Ventricular Rate (VR)
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Total Bilirubin
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in RR Interval
NCT00619801 (13) [back to overview]	Absolute Value of QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) at Visit 3 (Day 7)
NCT00619801 (13) [back to overview]	Absolute Value of QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV)
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Alanine Aminotransferase (ALT)
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Aspartate Aminotransferase (AST)
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Blood Creatinine
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Blood Urea Nitrogen
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in PR Interval
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QRS Duration
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT Interval
NCT00619801 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)
NCT00621959 (2) [back to overview]	Mean 24-hour Reflective Total 5 Symptoms Score (T5SS)
NCT00621959 (2) [back to overview]	Change From Baseline in Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score
NCT00628108 (13) [back to overview]	Absolute Value of QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) at Visit 3 (Day 7)
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Ventricular Rate (VR)
NCT00628108 (13) [back to overview]	Absolute Value of QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV)
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Alanine Aminotransferase (ALT)
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Aspartate Aminontransferase (AST)
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Blood Creatinine
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Blood Urea Nitrogen
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in PR Interval
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QRS Duration
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT Interval
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in RR Interval
NCT00628108 (13) [back to overview]	Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Total Bilirubin
NCT00653224 (90) [back to overview]	Total Nasal Symptom Score (TNSS) Over the Second Week
NCT00653224 (90) [back to overview]	Total Nasal Symptom Score (TNSS) Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Total Ocular Symptom Score (TOSS) Over the First Week
NCT00653224 (90) [back to overview]	Total Ocular Symptom Score (TOSS) Over the Second Week
NCT00653224 (90) [back to overview]	Total Ocular Symptom Score (TOSS) Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Global Patient's Rating of Efficacy at Endpoint of the Two Week Treatment Period
NCT00653224 (90) [back to overview]	Global Physician's Rating of Efficacy at Endpoint During the Two Week Treatment Period
NCT00653224 (90) [back to overview]	Sleepiness According to Epworth Sleepiness Scale (ESS) Score at Baseline and at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 1 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Work Time Missed Due to Allergy at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Epworth Sleepiness Scale (ESS) Score at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Epworth Sleepiness Scale (ESS) Score at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in Epworth Sleepiness Scale (ESS) Score at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in Overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Score at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Activities Score at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Activities Score at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Activities Score at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Emotional Score at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Emotional Score at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Emotional Score at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Eye Symptoms Score at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Eye Symptoms Score at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Eye Symptoms Score at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Nasal Symptoms Score at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Nasal Symptoms Score at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Nasal Symptoms Score at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Non-nose/Eye Symptoms Score at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Non-nose/Eye Symptoms Score at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Non-nose/Eye Symptoms Score at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Practical Problems Score at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Practical Problems Score at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Practical Problems Score at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Sleep Score at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Sleep Score at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Sleep Score at Week 2
NCT00653224 (90) [back to overview]	Ocular Pruritus Score Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 1 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Work Time Missed Due to Allergy at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 1 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Work Time Missed Due to Allergy at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 2 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Impairment While Working Due to Allergy at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 2 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Impairment While Working Due to Allergy at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 2 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Impairment While Working Due to Allergy at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 3 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Overall Work Impairment Due to Allergy at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 3 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Overall Work Impairment Due to Allergy at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 3 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Overall Work Impairment Due to Allergy at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 4 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Class Time Missed Due to Allergy at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 4 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Class Time Missed Due to Allergy at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 4 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Class Time Missed Due to Allergy at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 5 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Impairment in the Classroom Due to Allergy at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 5 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Impairment in the Classroom Due to Allergy at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 5 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Impairment in the Classroom Due to Allergy at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 6 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Overall Classroom Impairment Due to Allergy at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 6 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Overall Classroom Impairment Due to Allergy at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 6 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Overall Classroom Impairment Due to Allergy at Week 2
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 7 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Activity Impairment Due to Allergy at Endpoint During the Two-week Treatment Period
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 7 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Activity Impairment Due to Allergy at Week 1
NCT00653224 (90) [back to overview]	Change From Baseline in the Dimension 7 Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Score: Percentage of Activity Impairment Due to Allergy at Week 2
NCT00653224 (90) [back to overview]	Mean 24-hour Reflective Total 5 Symptoms Score (T5SS) Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Nasal Congestion Score Over the First Week
NCT00653224 (90) [back to overview]	Nasal Congestion Score Over the Second Week
NCT00653224 (90) [back to overview]	Nasal Congestion Score Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Nasal Pruritus Score Over the First Week
NCT00653224 (90) [back to overview]	Nasal Pruritus Score Over the Second Week
NCT00653224 (90) [back to overview]	Nasal Pruritus Score Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Ocular Itching/Burning Score Over the First Week
NCT00653224 (90) [back to overview]	Ocular Itching/Burning Score Over the Second Week
NCT00653224 (90) [back to overview]	Ocular Itching/Burning Score Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Ocular Pruritus Score Over the First Week
NCT00653224 (90) [back to overview]	Ocular Pruritus Score Over the Second Week
NCT00653224 (90) [back to overview]	Ocular Redness Score Over the First Week
NCT00653224 (90) [back to overview]	Ocular Redness Score Over the Second Week
NCT00653224 (90) [back to overview]	Ocular Redness Score Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Ocular Tearing/Watering Score Over the First Week
NCT00653224 (90) [back to overview]	Ocular Tearing/Watering Score Over the Second Week
NCT00653224 (90) [back to overview]	Ocular Tearing/Watering Score Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Post-nasal Drip Score Over the First Week
NCT00653224 (90) [back to overview]	Post-nasal Drip Score Over the Second Week
NCT00653224 (90) [back to overview]	Post-nasal Drip Score Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Rhinorrhea Score Over the First Week
NCT00653224 (90) [back to overview]	Rhinorrhea Score Over the Second Week
NCT00653224 (90) [back to overview]	Rhinorrhea Score Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Sneezing Score Over the First Week
NCT00653224 (90) [back to overview]	Sneezing Score Over the Second Week
NCT00653224 (90) [back to overview]	Sneezing Score Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Total 4 Symptoms Score (T4SS) Over the First Week
NCT00653224 (90) [back to overview]	Total 4 Symptoms Score (T4SS) Over the Second Week
NCT00653224 (90) [back to overview]	Total 4 Symptoms Score (T4SS) Over the Total Treatment Period (14 Days)
NCT00653224 (90) [back to overview]	Total 5 Symptoms Score (T5SS) Over the First Week
NCT00653224 (90) [back to overview]	Total 5 Symptoms Score (T5SS) Over the Second Week
NCT00653224 (90) [back to overview]	Total Nasal Symptom Score (TNSS) Over the First Week
NCT00826943 (3) [back to overview]	Modified Epworth Sleepiness Scale
NCT00826943 (3) [back to overview]	Likert Score Rating Global Sedation
NCT00826943 (3) [back to overview]	Total Four Symptom Scores (Allergy Symptoms)
NCT00884325 (2) [back to overview]	Dermatology Life Quality Index (DLQI) Questionnaire Scores at Baseline, Week 2 and Week 4
NCT00884325 (2) [back to overview]	Pruritus VAS Scores at Baseline, Week 2 and Week 4
NCT01392859 (1) [back to overview]	Characterize Contribution of Histamine in Children With Asthma
NCT01563081 (5) [back to overview]	Cmax and Cmin of Levocetirizine in Plasma
NCT01563081 (5) [back to overview]	Number of Participants Categorized With the Indicated Pruritis Severity on the First Day of Treatment and at Weeks 1 and 2/Early Withdrawal
NCT01563081 (5) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs)
NCT01563081 (5) [back to overview]	Number of Participants With the Indicated Change From the First Day of Treatment in Allergic Rhinitis and Pruritis Associated With Skin Diseases at Weeks 1 and 2/EW, as Assessed by the Investigator/Sub-investigator Based on Legal Representative Impression
NCT01563081 (5) [back to overview]	Number of Participants With the Indicated Change From the First Day of Treatment in Nasal Symptoms and Pruritis Associated With Skin Diseases at Weeks 1 and 2/Early Withdrawal, as Assessed by the Investigator or Sub-investigator
NCT01586091 (3) [back to overview]	Flaire Diameter (mm)
NCT01586091 (3) [back to overview]	Pruritus as Assessed by the VAS Score
NCT01586091 (3) [back to overview]	Wheal Volume (cm3)
NCT01722162 (3) [back to overview]	Progression Free Survival (Arm A)
NCT01722162 (3) [back to overview]	Incidence and Severity of Adverse Events as Measured by Number of Participants Who Experience Grade 3 and Higher Adverse Events
NCT01722162 (3) [back to overview]	Progression Free Survival (Arm B)
NCT03555890 (64) [back to overview]	Part 2: Number of Participants With AEs and SAEs
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in SBP and DBP
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in PR Interval, QRS Interval, QT Interval and QTcF Interval
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Platelet Count and White Blood Cell Count
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Heart Rate (ECG)
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Heart Rate
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid Levels
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Calcium, Cholesterol, Chloride, Glucose, High Density Lipids Cholesterol, Potassium, Low Density Lipids Cholesterol, Sodium, Phosphorus Inorganic, Triglycerides and Urea/BUN Levels
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Body Temperature
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils Count
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase Levels
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Albumin and Total Protein Levels
NCT03555890 (64) [back to overview]	Part 1: Urine Specific Gravity
NCT03555890 (64) [back to overview]	Part 1: Urine Potential of Hydrogen (pH)
NCT03555890 (64) [back to overview]	Part 1: Number of Participants With Urinalysis Results by Dipstick Method
NCT03555890 (64) [back to overview]	Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in PR Interval, QRS Interval, QT Interval and QTcF Interval
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Platelet Count and White Blood Cell Count
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Heart Rate (12-Lead Electrocardiogram [ECG])
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Heart Rate
NCT03555890 (64) [back to overview]	Part 1: Apparent Terminal Phase Half-life (t1/2) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Calcium, Cholesterol, Chloride, Glucose, High Density Lipids Cholesterol, Potassium, Low Density Lipids Cholesterol, Sodium, Phosphorus Inorganic, Triglycerides and Urea/Blood Urea Nitrogen (BUN) Levels
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Body Temperature
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils Count
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Albumin and Total Protein Levels
NCT03555890 (64) [back to overview]	Part 2: Vz/F of Levocetirizine
NCT03555890 (64) [back to overview]	Part 2: Tmax of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Apparent Clearance Following Oral Dosing (CL/F) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 2: t1/2 of Levocetirizine
NCT03555890 (64) [back to overview]	Part 2: MRT of Levocetirizine
NCT03555890 (64) [back to overview]	Part 2: Kel (lambda_z) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 2: Cmax of Levocetirizine
NCT03555890 (64) [back to overview]	Part 2: CL/F of Levocetirizine
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Reticulocytes
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Red Blood Cell Count
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Mean Corpuscle Volume
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Mean Corpuscle Hemoglobin
NCT03555890 (64) [back to overview]	Part 2: Change From Baseline in Amylase Levels
NCT03555890 (64) [back to overview]	Part 2: Change Form Baseline in Hematocrit
NCT03555890 (64) [back to overview]	Part 2: AUC(0-t) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Apparent Volume of Distribution Following Oral Dosing (Vz/F) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 2: %AUCex of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Time to First Occurrence of Cmax (Tmax) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Mean Residence Time (MRT) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Maximum Observed Concentration (Cmax) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Elimination Rate Constant (Kel) (lambda_z) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Reticulocytes
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Red Blood Cell Count
NCT03555890 (64) [back to overview]	Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero Time (Pre-dose) to the Time of Last Quantifiable Concentration (AUC[0-t]) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid Levels
NCT03555890 (64) [back to overview]	Part 1: Area Under the Concentration-time Curve From Zero Time (Pre-dose) Extrapolated to Infinite Time AUC(0-inf) of Levocetirizine
NCT03555890 (64) [back to overview]	Part 1: Change Form Baseline in Hematocrit
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Amylase Levels
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Mean Corpuscle Hemoglobin
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Mean Corpuscle Volume
NCT03555890 (64) [back to overview]	Part 1: Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase Levels
NCT03555890 (64) [back to overview]	Part 2: Urine Specific Gravity
NCT03555890 (64) [back to overview]	Part 2: Urine Potential of Hydrogen (pH)
NCT03555890 (64) [back to overview]	Part 2: Number of Participants With Urinalysis Results by Dipstick Method
NCT03555890 (64) [back to overview]	Part 2: AUC(0-inf) of Levocetirizine

Percentage of Days With Symptoms of Nocturnal Cough

The caring person was to note on the diary card each nocturnal cough event with sleep disturbances occurring from 7:00 pm to 7:00 am (NCT00152464)
Timeframe: During the treatment period (18 months)

Intervention	percentage of days (Mean)
Placebo (PBO)	2.72
Levocetirizine (LCTZ)	2.33

Intervention	percentage of subjects (Number)
	Topical corticosteroids	Local Steroids Class A, NSAI creams, tar	Local Steroids Class B	Local Steroids Class C	Topical tacrolimus	Topical pimecrolimus	Systemic H1 anti-histamines	Local antibiotics or antiseptics
Levocetirizine (LCTZ)	63.9	33.3	27.1	37.3	1.2	5.5	19.6	11.0
Placebo (PBO)	61.6	31.4	28.6	33.7	0.8	2.4	22.0	12.9

Intervention	percentage of days (Mean)
	Beta 2 Mimetics	Cromoglycates	Inhaled Corticoids	Systemic Corticoids	Leukotriene antagonists
Levocetirizine (LCTZ)	1.37	0.09	1.98	0.13	0.34
Placebo (PBO)	2.36	0.03	3.60	0.31	0.30

Intervention	percentage of days (Mean)
	Topical corticosteroids	LSC A, NSAI creams, tar	LSC B	LSC C	Topical tacrolimus	Topical pimecrolimus	Systemic H1 a-h	Local ABs or antiseptics
Levocetirizine (LCTZ)	31.84	18.64	12.30	8.27	0.02	0.31	1.95	2.63
Placebo (PBO)	32.42	15.40	14.23	9.82	0.36	0.52	3.80	2.99

Intervention	units on a scale (Least Squares Mean)
	Sneezing Score	Rhinorrhea Score	Nasal Pruritus Score	Ocular Pruritus Score	Nasal Congestion Score
Continuous Treatment (CT)	0.82	0.80	0.71	0.55	0.87
On Demand Treatment (ODT)	0.94	0.80	0.74	0.68	1.08

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-3.80
Levocetirizine (LCTZ) 2.5 mg	-7.15
Levocetirizine (LCTZ) 5 mg	-7.05
Cetirizine (CTZ) 5 mg	-7.93
Cetirizine (CTZ) 10 mg	-7.54

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-3.61
Levocetirizine (LCTZ) 2.5 mg	-6.80
Levocetirizine (LCTZ) 5 mg	-7.10
Cetirizine (CTZ) 5 mg	-7.43
Cetirizine (CTZ) 10 mg	-7.72

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-6.55
Levocetirizine (LCTZ) 2.5 mg	-11.33
Levocetirizine (LCTZ) 5 mg	-11.27
Cetirizine (CTZ) 5 mg	-12.71
Cetirizine (CTZ) 10 mg	-11.74

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-3.50
Levocetirizine (LCTZ) 2.5 mg	-6.35
Levocetirizine (LCTZ) 5 mg	-7.07
Cetirizine (CTZ) 5 mg	-6.78
Cetirizine (CTZ) 10 mg	-7.92

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-5.73
Levocetirizine (LCTZ) 2.5 mg	-10.25
Levocetirizine (LCTZ) 5 mg	-11.03
Cetirizine (CTZ) 5 mg	-10.73
Cetirizine (CTZ) 10 mg	-12.14

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-6.10
Levocetirizine (LCTZ) 2.5 mg	-10.86
Levocetirizine (LCTZ) 5 mg	-11.22
Cetirizine (CTZ) 5 mg	-11.84
Cetirizine (CTZ) 10 mg	-11.92

Intervention	units on a scale (Least Squares Mean)
	Runny Nose Score	Itchy Nose Score	Sniffles Score	Nose Blow Score	Sneezes Score	Watery Eyes Score
Cetirizine (CTZ) 10 mg	-1.04	-1.10	-1.10	-1.96	-1.23	-1.07
Cetirizine (CTZ) 5 mg	-1.17	-1.28	-1.24	-1.92	-1.22	-1.13
Levocetirizine (LCTZ) 2.5 mg	-1.01	-1.03	-1.15	-1.87	-1.15	-0.94
Levocetirizine (LCTZ) 5 mg	-0.95	-1.09	-1.06	-1.82	-1.07	-1.08
Placebo (PBO)	-0.60	-0.66	-0.65	-0.98	-0.37	-0.56

Intervention	percentage of participants (Number)
Placebo (PBO)	23.1
Levocetirizine (LCTZ)	49.4
Montelukast (MLKT)	32.9

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-5.92
Levocetirizine (LCTZ)	-12.21
Montelukast (MLKT)	-9.28

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-2.65
Levocetirizine (LCTZ)	-9.97
Montelukast (MLKT)	-5.47

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-6.57
Levocetirizine (LCTZ)	-11.15
Montelukast (MLKT)	-9.65

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-5.53
Levocetirizine (LCTZ)	-11.54
Montelukast (MLKT)	-8.68

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-5.91
Levocetirizine (LCTZ)	-13.39
Montelukast (MLKT)	-9.73

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-2.45
Levocetirizine (LCTZ)	-9.54
Montelukast (MLKT)	-5.12

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-3.16
Levocetirizine (LCTZ)	-7.37
Montelukast (MLKT)	-5.48

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-3.46
Levocetirizine (LCTZ)	-6.58
Montelukast (MLKT)	-5.65

chemdatabank.com

levocetirizine

Cross-References

Synonyms (80)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Pathways (1)

Protein Targets (8)

Potency Measurements

Bioassays (27)

Research

Studies (254)

Market Indicators

Research Demand Index: 127.31

Study Types

Clinical Trials (69)

Trial Overview

Trial Outcomes

Percentage of Days With Symptoms of Nocturnal Cough

Percentage of Subjects Using Medication for Atopic Dermatitis

Number of Episodes of Urticaria Per Subject

Percentage of Days With Symptoms of Either Wheezing or Nocturnal Cough

Percentage of Days With Symptoms of Wheezing

Percentage of Subjects With Urticaria

Time to Onset of Asthma During the Treatment Period

Percentage of Days of Use of Asthma Medication

Percentage of Days of Use of Medication for Atopic Dermatitis

Percentage of Subjects Using Asthma Medication

Mean Weekly Individual Symptoms Scores During the Treatment Period

Mean Monthly Individual Symptoms Scores During Month 6 of the Treatment Period

Mean Monthly Individual Symptoms Scores During Month 5 of the Treatment Period

Mean Monthly Individual Symptoms Scores During Month 4 of the Treatment Period

Mean Monthly Individual Symptoms Scores During Month 3 of the Treatment Period

Mean Monthly Individual Symptoms Scores During Month 2 of the Treatment Period

Mean Monthly Individual Symptoms Scores During Month 1 of the Treatment Period

Mean Weekly Total 4 Symptom Score (T4SS) During the Treatment Period

Mean Monthly Total 4 Symptom Score (T4SS) for Month 6 of the Treatment Period

Mean Monthly Total 4 Symptom Score (T4SS) for Month 5 of the Treatment Period

Mean Monthly Total 4 Symptom Score (T4SS) for Month 3 of the Treatment Period

Mean Monthly Total 4 Symptom Score (T4SS) for Month 2 of the Treatment Period

Mean Monthly Total 4 Symptom Score (T4SS) for Month 1 of the Treatment Period

Mean Monthly Total 4 Symptom Score (T4SS) for Month 4 of the Treatment Period

Mean Score for Pruritus Duration Over the Four Weeks of Treatment

Mean Pruritus Severity Score Over the Four Weeks of Treatment

Mean Chronic Idiopathic Urticaria (CIU) Composite Score Over the First Week of Treatment

Mean Pruritus Severity Score Over the First Week of Treatment

Mean Chronic Idiopathic Urticaria (CIU) Composite Score Over the Four Weeks of Treatment

Mean Score for Pruritus Duration Over the First Week of Treatment

Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I

Change From Baseline in the MSC Score Over the Total Treatment Period (Period I + Period II)

Change From Baseline in the Total Symptom Complex (TSC) Score Over Period I

Change From Baseline in the MSC Score Over Period II

Change From Baseline in the Total Symptom Complex (TSC) Score Over Period II

Change From Baseline in the Total Symptom Complex (TSC) Score Over the Total Treatment Period (Period I + Period II)

Change From Baseline in the Individual Symptom Scores Over Period I

Change From Baseline in the Individual Symptom Scores Over Period II

Change From Baseline in the Individual Symptom Scores Over the Total Treatment Period (Period I + Period II)

Percentage of Subjects, at the End of Period III Who Are Willing to Take the Same Medication During the Next Pollen Season

Onset of Action During Period I

Global Satisfaction of the Subjects at the End of Period III

Change From Baseline in the TSC Score + Nasal Congestion Score Over the Total Treatment Period (Period I + Period II + Period III)

Change From Baseline in the TSC Score + Nasal Congestion Score Over Period III

Change From Baseline in the TSC Score + Nasal Congestion Score Over Period II

Change From Baseline in the TSC Score + Nasal Congestion Score Over Period I

Change From Baseline in the Total Symptom Complex (TSC) Score Over the Total Treatment Period (Period I + Period II + Period III)

Change From Baseline in the Total Symptom Complex (TSC) Score Over Period III

Change From Baseline in the Total Symptom Complex (TSC) Score Over Period II

Change From Baseline in the Individual Symptom Scores Over Period I

Change From Baseline in the MSC Score Over the Total Treatment Period (Period I + Period II + Period III)

Change From Baseline in the MSC Score Over Period III

Change From Baseline in the MSC Score Over Period II

Change From Baseline in the Major Symptom Complex (MSC) Score Over Period I

Intervention	units on a scale (Least Squares Mean)
Placebo (PBO)	-6.16
Levocetirizine (LCTZ)	-10.53
Montelukast (MLKT)	-9.01

Intervention	percentage of participants (Number)
	< 20%	20%-35%	35%-50%	50%-65%	65%-80%	>=80%
Levocetirizine (LCTZ)	16.7	17.9	13.5	14.1	17.9	19.9
Montelukast (MLKT)	31.8	14.6	17.2	17.2	14.6	4.6
Placebo (PBO)	48.1	21.2	15.4	3.8	8.7	2.9

Intervention	percentage of participants (Number)
	< 20%	>= 20%	< 50%	>= 50%	< 70%	>= 70%
Levocetirizine (LCTZ)	16.7	83.3	48.1	51.9	69.9	30.1
Montelukast (MLKT)	31.8	68.2	63.6	36.4	86.1	13.9
Placebo (PBO)	48.1	51.9	84.6	15.4	89.4	10.6

Intervention	minutes (Median)
Placebo (PBO)	101.02
Levocetirizine (LCTZ)	70.02
Montelukast (MLKT)	63.02

Intervention	Days (Mean)
Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule	5
Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule	4
Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule	NA

Intervention	Participants (Number)
	Marked improvement	Moderate improvement	Mild improvement	No change	Exacerbation
Cetirizine	52	54	47	15	1
Levocetirizine	47	62	39	18	1

Intervention	participants (Number)
	Marked Worsening	Moderate Worsening	Slight Worsening	No Change	Slight Improvement	Moderate Improvement	Marked Improvement
Levocetirizine	6	11	8	69	95	62	33
Placebo	14	16	21	86	81	52	22

Intervention	participants (Number)
	ESS score < 8 at Baseline and < 8 at Endpoint	ESS score < 8 at Baseline and ≥ 8 at Endpoint	ESS score ≥ 8 at Baseline and < 8 at Endpoint	ESS score ≥ 8 at Baseline and ≥ 8 at Endpoint
Levocetirizine	63	13	57	151
Placebo	66	16	46	165

Intervention	units on a scale (Median)
	DLQI - Baseline	DLQI - Week 2	DLQI - Week 4
Subjects Receiving Placebo	8.00	5.5	4.00
Subjects Receiving Xyzal	7.5	3.5	2.00

Intervention	units on a scale (Median)
	Baseline	Week 2	Week 4
Subjects Receiving Placebo	7.5	5.9	6.4
Subjects Receiving Xyzal	7.8	6.10	4.15